

**Table S1** Univariate and multivariate analyses of predictors associated with SVI (containing CAPRA score)

Variable	Univariate		Multivariate	
	OR (95% CI)	P value	OR (95% CI)	P value
Age (y)	0.990 (0.944–1.039)	0.694		
BMI (kg/m <sup>2</sup> )	1.038 (0.903–1.193)	0.599		
PSA (ng/mL)	1.211 (0.955–1.536)	0.114		
f/t PSA	0.014 (0.000–25.202)	0.266		
PV (mL)	0.984 (0.962–1.006)	0.150		
PSAD (ng/mL <sup>2</sup> )	12.465 (0.477–325.419)	0.130		
The percentage of positive systematic biopsies	1.019 (1.002–1.036)	0.028*		
Maximum cancer percentage per core	1.019 (1.003–1.035)	0.018*		0.170
Clinical stage, No. (%)	1.113 (0.806–1.594)	0.473		
T1c				
T2a				
T2b				
T2C				
T3a				
CAPRA score	1.388 (1.063–1.814)	0.016*		0.179
PI-RADS	4.095 (1.688–9.938)	0.002*	4.095 (1.688–9.938)	0.002*
Negative				
Suspicious				
Positive				
GGG	1.747 (1.284–2.378)	<0.001*		
1				
2				
3				
4				
5				

SVI, seminal vesicle invasion; OR, odd ratios; CI, confidence interval; BMI, body mass index; PSA, prostate-specific antigen; f/t PSA, free/total prostate-specific antigen ratio; PV, prostate volume; PSAD, PSA density; CAPRA, cancer of the prostate risk assessment; PI-RADS, Prostate Imaging Reporting and Data System; GGG, Gleason grade group; \*, P value with <0.05 significance.